Limitations in doxorubicin production from Streptomyces peucetius.
Doxorubicin (DXR), produced by Streptomyces peucetius ATCC 27952, exhibits potent antitumor activity against various cancer cell lines. Considerable time has lapsed since the biosynthesis of DXR and its overproduction was first summarized. Based on biosynthetic studies and product analysis, various factors affecting its production by the parental strain, S. peucetius ATCC 27952, are reviewed to better circumvent any bottlenecks in DXR production, thereby providing ideas to genetically engineered industrial strains of S. peucetius.
Malla
Sailesh
S
Institute of Biomolecule Reconstruction (iBR), Department of Pharmaceutical Engineering, Sun Moon University, #100, Kalsan-ri, Tangjeong-myeon, Asansi, Chungnam 336-708, Korea (ROK).
Niraula
Narayan Prasad
NP
Singh
Bijay
B
Liou
Kwangkyoung
K
Sohng
Jae Kyung
JK
D018943:Anthracyclines / Q000378:metabolism; D053898:Biosynthetic Pathways; D065607:Cytochrome P-450 Enzyme Inhibitors; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D025461:Feedback, Physiological; D006031:Glycosylation; D006595:Hexosamines / Q000096:biosynthesis; D013302:Streptomyces / Q000378:metabolism*
D018943:Anthracyclines; D065607:Cytochrome P-450 Enzyme Inhibitors; D006595:Hexosamines; C015490:rhodomycinone; C007217:daunosamine; D004317:Doxorubicin